ArticleThe American journal of case reports2025
Behçet Disease and Cognitive Impairment: A Case Study of an Overlooked Symptom.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Behçet disease (BD) is a rare systemic vasculitis with diverse clinical manifestations, most commonly oral ulcers. Neurological involvement occurs in 5% to 15% of cases, often presenting as brainstem and myelopathic syndromes. However, cognitive impairment can develop even in the absence of overt neurological signs. A case-control study using the Brief Repeatable Battery of Neuropsychological Tests reported cognitive dysfunction in 38% of BD patients lacking overt neurological symptoms, suggesting that the cognitive dysfunction was immune-mediated. This case report points to the importance of heightened clinical vigilance in patients with BD presenting with subtle cognitive changes, even in the absence of neurological involvement. Routine neuropsychological screening could enable earlier detection and timely intervention, thereby reducing the risk of irreversible cognitive decline. CASE REPORT A 59-year-old woman with BD presented with progressive cognitive impairment 1 year after diagnosis. She had no prior cognitive problems or focal neurological signs. Her comorbid thymoma and hyperthyroidism remained clinically stable. Cognitive screening (MoCA-INA 27/30) revealed deficits in memory and attention, supported by suboptimal performance on the Digit Span and Trail-Making tests. Brain magnetic resonance imaging (MRI) ruled out stroke or neurodegeneration but demonstrated bilateral parietal atrophy and mild white-matter hyperintensities in the temporal and occipital lobes. She received donepezil, folic acid, cognitive stimulation, and immunosuppressive therapy. At 1-year follow-up, the Montreal Cognitive Assessment (MoCA-INA) score had normalized (30/30), with improved neurocognitive performance and stable daily functioning. CONCLUSIONS This case shows that cognitive impairment can present as an isolated manifestation of BD, even in the absence of overt neurological symptoms. Early neuropsychological screening and timely intervention can prevent progression and preserve quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.